



If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 101(b) of the Securities Exchange Act

---

---

**Item 2.02. Results of Operations and Financial Condition.**

On April 25, 2024, we issued the press release furnished as Exhibit 99.1. The press release describes the operations for the quarter ended March 31, 2024.

The information furnished in this Current Report on Form 8-K under Item 2.02 and the attached exhibit shall be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, shall be expressly set forth by specific reference in such a filing.

**Item 8.01. Other Events.**

On April 25, 2024, we announced that our board of directors declared a quarterly cash dividend of US \$0.10. The dividend will have a record date of May 9, 2024, payable on June 13, 2024. The dividend will be paid in US dollar currency to holders of ResMed’s common stock trading on the New York Stock Exchange. Holders of CHS Instruments trading on the Australian Securities Exchange will receive an equivalent amount in Australian dollars based on the exchange rate on the record date, and reflecting the 10:1 ratio between CDIs and NYSE shares. The ex-dividend date will be May 8, 2024, for common stockholders and for CDI holders. ResMed has received approval from the ASX’s settlement operating rules, which will allow ResMed to defer processing conversions between common stock and CDI registers from May 8, 2024, through May 9, 2024, inclusive.

**Item 9.01. Financial Statements and Exhibits.**

(d) Exhibits

<u>Exhibits:</u>	<u>Description of Document</u>
99.1	<a href="#">Press Release dated April 25, 2024, regarding results of operations</a>
104	Cover Page Interactive Data File (embedded within the Inline XBRL, document)

---

## SIGNATURES

We have authorized the person whose signature appears below to sign this report on our behalf, in accordance with the Securities Exchange Act of 1934.

Date: April 25, 2024

**RESMED INC.**

(registrant)

By: /s/ Brett Sandercock

Name: Brett Sandercock

Its: Chief Financial Officer